StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Morgan Stanley Calls Moderna (MRNA) a Catalyst Driven Idea
January 5, 2023 4:09 PM
Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $209.00 price target on Moderna (NASDAQ: MRNA).The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
Moderna (MRNA) a catalyst driven idea at Morgan Stanley
January 6, 2023 12:17 PM
Morgan Stanley sees a risk to Pfizer's (PFE) EPS guidance
January 6, 2023 10:08 AM
Moderna (MRNA) and CytomX (CTMX) Enter Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
January 5, 2023 4:06 PM
Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
January 5, 2023 4:06 PM
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
January 5, 2023 4:05 PM
Moderna (MRNA) PT Raised to $195 at BofA Securities
January 4, 2023 10:24 AM
Moderna snaps up Japan's OriCiro Genomics in mRNA manufacturing push
January 4, 2023 7:13 AM
Moderna (MRNA) to acquire OriCiro Genomics K.K for $85 million
January 4, 2023 7:01 AM
Moderna to Acquire OriCiro Genomics
January 4, 2023 7:01 AM
Moderna (MRNA) CEO Issues Update to Shareholders
January 3, 2023 7:18 AM
Form 8-K Moderna, Inc. For: Jan 03
January 3, 2023 7:06 AM
Moderna to Provide Business and Pipeline Updates at the 2023 J.P. Morgan Healthcare Conference
January 3, 2023 7:01 AM
